EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study

Moran Lavie, Mika Rochman, Keren Armoni Domany, Inbal Golan Tripto, Moria Be'er, Omri Besor, Liora Sagi, Sharon Aharoni, Mira Ginsberg, Iris Noyman, Hagit Levine

European Journal of Pediatrics · 2024

DOI: 10.1007/s00431-024-05886-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Pediatrics, 2024. Verfasst von Moran Lavie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonology Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. moranla@tlvmc.gov.il. Hauptthemen laut MEDLINE: Respiratory Insufficiency, Spinal Muscular Atrophies of Childhood, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Onasemnogene abeparvovec (OA) is a novel gene replacement therapy for patients with spinal muscular atrophy (SMA). This study provides real-world respiratory data for pediatric SMA patients receiving OA who were assessed before and one year after treatment in a multicenter cohort study conducted from 2019 to 2021. Twenty-five OA-treated SMA patients (23 with type 1 and 2 with type 2; median age at treatment 6.1 months, with a range of 0.36–23 months) were included. Sixteen were treatment-naïve, and nine had received various prior treatments. Two patients died due to respiratory failure during the study period. Of the remaining 23 patients, four were put on non-invasive ventilation (NIV), bringing ventilated patients to a total of ten during the post-treatment year. Three patients required permanent NIV support, while 13 did not require any respiratory support. Ventilation time decreased from 14.3 to 11.1 hours per day, and respiratory hospitalizations decreased by 26% (from 0.76 to 0.57 per life year). Fifteen of the 23 patients maintained full oral nutrition at study closure compared to 20 of the 25 at study initiation. This real-world data analysis demonstrates that OA may improve respiratory outcomes in SMA patients. Importantly, compounding factors, such as age at treatment initiation, treatment combinations, and natural history, may influence the respiratory course, thus highlighting the need for standardized long-term management. What is Known: • Respiratory failure is a leading cause of mortality in untreated spinal muscular atrophy type 1 patients. • Onasemnogene abeparvovec (OA) improves neurological outcomes, but real-world respiratory data are limited. What is New: • Our real-world analysis suggests OA may improve respiratory outcomes. • Age at treatment and treatment combinations may also influence respiratory trajectory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory InsufficiencySpinal Muscular Atrophies of ChildhoodBiological ProductsHumansInfantMaleFemaleTreatment OutcomeNoninvasive VentilationCohort StudiesInfant, NewbornGenetic TherapyRecombinant Fusion Proteins

Stichwörter der Autor:innen

NusinersenOnasemnogene abeparvovecRespiratoryRestrictive lung diseaseSpinal muscular atrophy

Substanzen

ZolgensmaBiological ProductsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Pediatric Pulmonology Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. moranla@tlvmc.gov.il.
  • Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. moranla@tlvmc.gov.il.
  • Pediatric Pulmonology Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Pediatric Pulmonology Unit, Sylvan Adams Children's Hospital, E. Wolfson Medical Center, Holon, Israel.
  • Pediatric Pulmonary Unit, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheba, Israel.

Förderung

  • Tel Aviv University

Zitieren

APA

Lavie, M., Rochman, M., Armoni Domany, K., Golan Tripto, I., Be'er, M., Besor, O., Sagi, L., Aharoni, S., Ginsberg, M., Noyman, I., & Levine, H. (2024). Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study. European Journal of Pediatrics. https://doi.org/10.1007/s00431-024-05886-9

Vancouver

Lavie M, Rochman M, Armoni Domany K, Golan Tripto I, Be'er M, Besor O, et al. Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study. European Journal of Pediatrics. 2024. doi:10.1007/s00431-024-05886-9

BibTeX
@article{Lavie2024,
  author = {Lavie, Moran and Rochman, Mika and Armoni Domany, Keren and Golan Tripto, Inbal and Be'er, Moria and Besor, Omri and Sagi, Liora and Aharoni, Sharon and Ginsberg, Mira and Noyman, Iris and Levine, Hagit},
  title = {Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study},
  journal = {European Journal of Pediatrics},
  year = {2024},
  doi = {10.1007/s00431-024-05886-9}
}
Kostenlos starten →